No Data
The Hong Kong stock market is restructuring the value of pharmaceuticals! Hengrui Medicine has received a premium binding from AstraZeneca, and the stock price once rose over 20%.
① Does the offshore strategy mean that "technology platform premium + international certification" is replacing the traditional PE valuation method as the core logic for valuing Innovative Drugs companies? ② With JACOBIO-B narrowing its annual loss by 56.6% through its core product Galidesivir, can it be inferred that China’s Innovative Drugs companies have broken through the industry curse of "burning money on R&D - ongoing losses"?
Hutchmed (China) Wins Conditional Approval for Lymphoma Treatment
Hutchmed (China) (00013.HK) announced that Tazemetostat has received conditional approval from the National Medical Products Administration of China for the treatment of relapsed or refractory follicular lymphoma.
On March 21, Gelonghui reported that Hutchmed (China) (00013.HK) announced that the new drug application for Tazverik (tazemetostat) has received conditional approval in China for the treatment of adult patients with EZH2 mutation positive relapsed or refractory follicular lymphoma (FL) who have previously received at least two systemic therapies. This approval was obtained through the priority review procedure of the National Medical Products Administration ("NMPA") in China and also marks the first national regulatory approval for Tazverik in China. The conditional approval from the NMPA was based on a study.
Express News | HUTCHMED Announces That The New Drug Application For TAZVERIK (Tazemetostat) Has Been Granted Conditional Approval In China For The Treatment Of Adult Patients With Relapsed Or Refractory Follicular Lymphoma With EZH2 Mutation Who Have Received At...
Express News | HUTCHMED Announces Nmpa Conditional Approval for Tazverik® (Tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
HUTCHMED's Strong Financial Performance and Strategic Growth Drive Buy Rating
